HSBC Small Cap Fund
The Scheme will primarily be a diversified equity fund which will invest predominantly in small cap stocks to generate long term capital appreciation.
Growthvine rating: 3/5 — ranked #13 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹90.40 (as of 2026-11-13) |
|---|
| AUM | ₹18,513 Cr |
|---|
| Expense ratio | 1.43% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dipan S. Parikh |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 365 days |
|---|
Performance & risk
| Sharpe ratio | 0.32 |
|---|
| Standard deviation | 22.42% |
|---|
| Max drawdown | −27.33% |
|---|
| Alpha | -0.07 |
|---|
| Beta | 0.99 |
|---|
Over 5 years, captured 91.3% of NIFTY Smallcap 250's upside and 88.1% of its downside.
Market cap allocation
| Large cap | 1.3% |
|---|
| Mid cap | 22.1% |
|---|
| Small cap | 76.5% |
|---|
Concentration
| Top 5 holdings | 12.1% |
|---|
| Top 10 holdings | 22.5% |
|---|
| Total holdings | 108 |
|---|
| Index overlap | 28.1% |
|---|
| Active share | 71.9% |
|---|
Top holdings
- Apar Industries Ltd — 2.6%
- Ather Energy Limited — 2.4%
- Sai Life Sciences Limited — 2.4%
- Karur Vysya Bank Ltd. — 2.4%
- Federal Bank Ltd. — 2.2%
- Navin Fluorine International Limited — 2.1%
- Vijaya Diagnostic Centre Limited — 2.1%
- Radico Khaitan Ltd. — 2.1%
- WELSPUN LIVING LIMITED — 2.0%
- Laurus Labs Limited — 2.0%
Top sectors
- Industrial Products — 15.3%
- Banking & Financial — 14.6%
- Pharma & Biotech — 10.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 15.4% | Q2 | #14 of 34 |
| 2025 | −11.5% | Q4 (Bottom) | #28 of 30 |
| 2024 | 28.5% | Q2 | #8 of 28 |
| 2023 | 46.1% | Q2 | #8 of 24 |